Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P00746
UPID:
CFAD_HUMAN
Alternative names:
Adipsin; C3 convertase activator; Properdin factor D
Alternative UPACC:
P00746; B4DV76; Q5U5S1; Q86VJ5; Q8N4E0; Q8WZB4
Background:
Complement factor D, also known as adipsin, plays a crucial role in the immune system by activating the C3 convertase of the alternate pathway. This activation is pivotal for the cleavage of factor B when complexed with C3b, mirroring the function of C1s in the classical pathway.
Therapeutic significance:
Complement factor D deficiency leads to increased susceptibility to bacterial infections, especially Neisseria, due to a defect in the alternative complement pathway. This highlights the protein's potential as a target for therapeutic interventions in immunologic disorders.